Nanotechnology-COVID-19 interface /

Saved in:
Bibliographic Details
Author / Creator:T., Devasena, author.
Imprint:Singapore : Springer, [2021]
Description:1 online resource.
Language:English
Series:SpringerBriefs in applied sciences and technology. Nanotheranostics.
SpringerBriefs in applied sciences and technology. Nanotheranostics.
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/12610515
Hidden Bibliographic Details
ISBN:9789813363007
9813363002
9813362995
9789813362994
Notes:Includes bibliographical references.
Description based on online resource; title from digital title page (viewed on March 11, 2021).
Summary:This book highlights the role of nanotechnology concepts in the management of COVID-19 pandemic. The book covers different aspects of the causative agent SARS CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2) and the COVID-19 pandemic with a special emphasis on nanotechnology. It discusses the origin and history of SARS CoV2 and the outbreak of COVID-19 and highlights the geographical mutations in the SARS CoV2 virus genome, providing information about the structural features, antigenicity and the life cycle of SARS CoV2. The book provides an insight into nanotechnology-virology interface and explains how nanomaterials link the gap between the vital phases of SARS CoV2 life cycle and the four modalities of COVID-19 management viz sensing/diagnosis, therapy, prevention and self-protection. Further, the existing and promising diagnostic tools for detection of COVID-19 are discussed with an emphasis on nano PCR, nanoimmunosensors, biobarcode assay and point of care approach and also describe the nanoparticles involved in the CT imaging of lungs and SFHI (Spatial Frequency Hetrodyne Imaging) for diagnosis of SARS COV2 infection. The book concludes with details about translational medicine and explains the types of SARS CoV2 vaccines, stages of COVID-19 vaccine development and possible nanovaccines for COVID-19, followed by the description on biopharmaceutical companies involved in the production of SARS CoV2 vaccines.
Other form:Print version: 9813362995 9789813362994
Standard no.:10.1007/978-981-33-6300-7